Download MendeleyCharacterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Guo, M., Dai, S., Wu, D., Duan, Y., Li, J., Qu, L., Jiang, L., Chen, Z., Chen, X., Chen, Y.(2020) Bioorg Med Chem Lett 34: 127757-127757
- PubMed: 33359446
- DOI: https://doi.org/10.1016/j.bmcl.2020.127757
- Primary Citation of Related Structures:
6L8L - PubMed Abstract:
Ibrutinib is a BTK-targeted irreversible inhibitor. In this study, we demonstrate that ibrutinib potently inhibits SRC activity in a non-covalent manner via mass spectrometry and crystallography. The S345C mutation renders SRC to bind covalently with ibrutinib, and restores the potency of ibrutinib against the gatekeeper mutant. The co-crystal structure of ibrutinib/SRC shows Ser345 of SRC did not form covalent bond with ibrutinib, leading to a decrease of potency and loss of the ability to overcome the gatekeeper mutation of SRC. The X-ray crystallographic studies also provide structural insight into why ibrutinib behaves differently against gatekeeper mutants of different kinases.
Organizational Affiliation:
Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Laboratory of Structural Biology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
